Pharmacokinetics and Dosing Recommendations of Tenofovir Disoproxil Fumarate in Hepatic or Renal Impairment

Author： Kearney Brian P.   Yale Kitty   Shah Jaymin   Zhong Lijie   Flaherty John F.  

Publisher： Adis International

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.45, Iss.11, 2006-01, pp. : 1115-1124

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tenofovir disoproxil fumarate: Renal impairment, hypophosphataemia and osteomalacia: 2 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1083, 2006-01 ,pp. : 24-24

Adis International

Access to resources Recommend Favorite

Tenofovir Disoproxil Fumarate: Clinical Pharmacology and Pharmacokinetics

By Kearney B.P.   Flaherty J.F.   Shah J.  

Clinical Pharmacokinetics, Vol. 43, Iss. 9, 2004-01 ,pp. : 595-612

Adis International

Access to resources Recommend Favorite

Metformin/tenofovir disoproxil fumarate: Lactic acidosis and renal impairment in elderly patients: 2 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1386, 2012-01 ,pp. : 27-27

Adis International

Access to resources Recommend Favorite

Emtricitabine/Tenofovir Disoproxil Fumarate

By Adis International Limited  

Drugs in R&D, Vol. 5, Iss. 3, 2004-01 ,pp. : 160-161

Adis International

Access to resources Recommend Favorite

Emtricitabine/Tenofovir Disoproxil Fumarate

By Toni M. Dando   Antona J. Wagstaff  

Drugs, Vol. 64, Iss. 18, 2004-01 ,pp. : 2075-2082

Adis International

Access to resources Recommend Favorite